Burning Rock Biotech Limited (NASDAQ:BNR) previous close was $27.92 while the outstanding shares total 104.05M. BNR’s shares traded higher over the last trading session, gaining 1.61% on 06/17/21. The shares fell to a low of $27.85 before closing at $28.37. Intraday shares traded counted 0.49 million, which was -23.15% lower than its 30-day average trading volume of 397.87K. The stock’s Relative Strength Index (RSI) is 45.84, with weekly volatility at 5.55% and ATR at 2.19. The BNR stock’s 52-week price range has touched low of $18.64 and a $39.75 high.
Investors have identified the Diagnostics & Research company Burning Rock Biotech Limited as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.93 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Burning Rock Biotech Limited (BNR) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BNR, the company has in raw cash 322.49 million on their books with 6.12 million currently as liabilities. How the trend is over time is what investors should be concerned about. In terms of their assets, the company currently has 367.87 million total, with 41.99 million as their total liabilities.
Potential earnings growth for Burning Rock Biotech Limited (BNR)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 4.53 million trying to sell their products during the last quarter, with the result yielding a gross income of 11.74 million. This allows shareholders to hold on to 104.05M with the recently reported earning now reading -0.25 cents per share. This is a figure that compared to analyst’s prediction for their 08/17/2021 (-0.25 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.49 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BNR sounds very interesting.
Is the stock of BNR attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 0.13%.
3 out of 3 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Burning Rock Biotech Limited. 0 analysts has assigned a Sell rating on the BNR stock. The 12-month mean consensus price target for the company’s shares has been set at $23.13.